Related Experiment Video

Updated: Jul 17, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
16:40

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantable cardioverter defibrillators for prevention of sudden cardiac death

Rishi Sukhija1, Vimal Mehta, Marino Leonardi

  • 1Department of Internal Medicine, Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Clinical Cardiology
|January 31, 2007
PubMed

Insights

Sudden cardiac death (SCD) incidence is rising despite advances. Current risk prediction is inadequate, necessitating broader use of implantable cardioverter defibrillators (ICDs) and public defibrillation access.

Area of Science:

  • Cardiovascular Medicine
  • Electrophysiology
  • Public Health

Background:

  • Sudden cardiac death (SCD) remains a significant challenge in cardiovascular medicine, with incidence rates continuing to increase.
  • Current risk-stratification algorithms identify less than 25% of individuals who experience SCD, highlighting their limitations.
  • Many SCD events occur as the first presentation of cardiovascular disease, underscoring the need for improved preventative strategies.

Purpose of the Study:

  • To review the current understanding of sudden cardiac death (SCD) and its associated risk factors.
  • To discuss the limitations of existing risk-stratification methods for identifying individuals at high risk of SCD.
  • To explore current and future management strategies for reducing SCD, with a focus on implantable cardioverter defibrillators (ICDs) and public access defibrillation.

Main Methods:

  • Literature review of recent advances in cardiovascular medicine concerning sudden cardiac death.
  • Analysis of the efficacy and limitations of current risk-stratification algorithms.
  • Discussion of the role and implementation challenges of implantable cardioverter defibrillators (ICDs) and automated external defibrillators (AEDs).

Main Results:

  • Existing risk-stratification tools are insufficient for accurately identifying individuals at high risk for sudden cardiac death (SCD).
  • Increased utilization of implantable cardioverter defibrillators (ICDs) is anticipated, though their impact may be limited by SCD occurring as a first manifestation.
  • Effective public access defibrillation programs and widespread automated external defibrillator (AED) availability are crucial for managing out-of-hospital cardiac arrest.

Conclusions:

  • There is an urgent need for improved risk markers to better stratify patients for sudden cardiac death (SCD) risk.
  • Implantable cardioverter defibrillators (ICDs) will likely see increased use, but comprehensive strategies including public defibrillation are essential.
  • Enhancing public access defibrillation programs is critical for improving survival rates in out-of-hospital cardiac arrest scenarios.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...